Latest Diagnostics News

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.

Botala Energy confirms encouraging reservoir permeability at its Serowe-3.5B well in Botswana, setting the stage for hydraulic stimulation and production testing that could unlock commercial gas flows.

Ryder Capital posted a robust 33.53% pre-tax NTA return for FY26, far outpacing market benchmarks, and announced a fully franked 12 cents per share dividend for FY27, underscoring confidence in its small-cap portfolio.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

Compumedics reported a record $60.3 million in FY26 revenue, driven by an 18% year-on-year increase and a 70% jump in SaaS recurring revenues from Somfit and Nexus 360. The company resolved supply chain disruptions and targets faster EBITDA growth in FY27.

Archer Materials has raised $7 million through a placement and launched a $3 million share purchase plan, backing its strategic partnership with IonQ to develop sovereign quantum computing in Australia.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.